Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT07067905
EARLY_PHASE1
Clinical Evaluation of [68Ga]Ga-XT771 PET for Diagnosis in Patients With Glioblastoma and Clear Cell Renal Cell Carcinoma
Sponsor: Chinese PLA General Hospital
View on ClinicalTrials.gov
Summary
A prospective, open-label, phase 1 study. This clinical trial aims to evaluate the diagnostic value of 68Ga-XT771, a CAIX/CAXII protein-specific probe, in PET/CT imaging for patients with clear cell renal cell carcinoma and glioblastoma. Safety, tolerability, and biodistribution characteristics of 68Ga-XT771 will also be assessed.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
15
Start Date
2025-06-27
Completion Date
2026-06-01
Last Updated
2025-07-16
Healthy Volunteers
No
Interventions
DRUG
68Ga-XT771
68Ga-XT771 is injected intravenously with a dose of 4-8 mCi
Locations (1)
Chinese PLA General Hospital
Beijing, China